trending Market Intelligence /marketintelligence/en/news-insights/trending/p5ahLsa1O0tJZgmlRk4hpw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GSK-backed ViiV's 2-drug HIV shot rejected by US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

GSK-backed ViiV's 2-drug HIV shot rejected by US FDA

ViiV Healthcare Ltd. said the U.S. Food and Drug Administration rejected its investigational two-drug regimen for treating HIV-1 infection in virologically suppressed adults.

GlaxoSmithKline PLC-backed ViiV received a complete response letter from the U.S. regulator regarding its application for its long-acting combination of ViiV's cabotegravir and Johnson & Johnson's Edurant, or rilpivirine. The company said the reasons stated in the letter for the rejection relate to chemistry manufacturing and controls.

The company's new drug application was based on late-stage studies Atlas and Flair, which evaluated the two-drug regimen in 1,100 patients from 16 countries. The trials showed the combination worked as well as a standard-of-care, three-drug regimen in maintaining viral suppression throughout a 48-week period.

ViiV said it will work with the FDA to determine the next steps to take regarding the drug application.

U.K.-based ViiV and New Brunswick, N.J.-based Johnson & Johnson are developing the injectable regimen under a collaboration they entered in 2016. The drug combination was previously shown to be effective as an injection administered every two-months in a late-stage study.

ViiV is also seeking EU and Canada approval for the regimen. Pfizer Inc. and Shionogi & Co. Ltd. also own a stake in ViiV Healthcare.